BOONTON, N.J. Unigene Labs has appointed a new leader, the company said Wednesday.
Unigene announced the appointment of Ashleigh Palmer as president and CEO, replacing Warren Levy. Unigene is the developer of Fortical (calcitonin salmon [rDNA origin]), a nasal spray for treating postmenopausal osteoporosis. The company has since licensed U.S. rights to Fortical to Upsher-Smith Labs.
“We are delighted to welcome Ashleigh to the Unigene team,” Unigene chairman Richard Levy said. “His areas of expertise and understanding of Big Pharma, as well as his appreciation for our oral delivery platform and peptide manufacturing capabilities, will help ensure Unigene maximizes its core assets and existing partnerships.”